Abstract
Atherogenic lipids and chronic inflammation drive the development of cardiovascular disorders such as atherosclerosis. Many cardiovascular drugs target the liver which is involved in the formation of lipid and inflammatory risk factors. With robust systems biology tools and comprehensive bioinformatical packages becoming available and affordable, the effect of novel treatment strategies can be analyzed more comprehensively and with higher sensitivity. For example, beneficial as well as adverse effects of drugs can already be detected on the gene and metabolite level, and prior to their macroscopic manifestation. This chapter describes a systems approach for a prototype CV drug with established beneficial and adverse effects. All relevant steps, for example, experimental design, tissue collection and high quality RNA preparation, bioinformatical analysis of functional processes, and pathways (targeted and untargeted) are addressed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kleemann R, Kooistra T (2005) HMG-CoA reductase inhibitors: effects on chronic subacute inflammation and onset of atherosclerosis induced by dietary cholesterol. Curr Drug Targets Cardiovasc Haematol Disord 5:441–453
Kleemann R, Verschuren L, van Erk MJ et al (2007) Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 8:R200
Vergnes L, Phan J, Strauss M, Tafuri S, Reue K (2003) Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem 278:42774–42784
Kooistra T, Verschuren L, de Vries-van der Weij J et al (2006) Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 26:2322–2330
Tannock LR, O’Brien KD, Knopp RH et al (2005) Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 111:3058–3062
Nissen SE, Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294:2581–2586
Doggrell SA (2008) The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert Opin Pharmacother 9:875–878
Armitage J (2007) The safety of statins in clinical practice. Lancet 370:1781–1790
Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771:1065–1081
Choe SS, Choi AH, Lee JW et al (2007) Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic beta-cells. Diabetes 56:1534–1543
Nikolsky Y, Kirillov E, Zuev R, Rakhmatulin E, Nikolskaya T (2009) Functional analysis of OMICs data and small molecule compounds in an integrated “knowledge-based” platform. From the “Protein networks and pathway analysis” book. Humana, UK
Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T (2009) LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in ApoE*3Leiden mice: time course and mechanisms. J Lipid Res 50:301–311
Tontonoz P, Mangelsdorf DJ (2003) Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17:985–993
The Gene Ontology project in 2008 (2008) Nucleic Acids Res 36:D440–D444
Schroeder A, Mueller O, Stocker S et al (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7:3
Zadelaar S, Kleemann R, Verschuren L et al (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27:1706–1721
Black AE, Sinz MW, Hayes RN, Woolf TF (1998) Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 26:755–763
Verschuren L, Kooistra T, Bernhagen J et al (2009) MIF-deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance and associated atherosclerotic disease. Circ Res 105:99–107
Kleemann R, Zadelaar S, Kooistra T (2008) Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 79:360–376
Acknowledgments
The authors gratefully acknowledge support from the TNO research program “Personalized Health VP9” and from the National Cancer Institute (USA) SBIR grant “Systems Biology Platform to Study of Nutrient Compounds”. The authors thank Mrs Karin Toet for developing and optimizing an excellent RNA isolation protocol.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Nikolsky, Y., Kleemann, R. (2010). Systems Biology Approaches to the Study of Cardiovascular Drugs. In: Yan, Q. (eds) Systems Biology in Drug Discovery and Development. Methods in Molecular Biology, vol 662. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-800-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-60761-800-3_11
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-799-0
Online ISBN: 978-1-60761-800-3
eBook Packages: Springer Protocols